Constellation Alpha Capital Corp
Constellation Alpha Capital — DermTech — Investor Presentation (January 2020)
32 slides from Constellation Alpha Capital's investor presentation, Jan 21, 2020
Slide 1: Investor Presentation Q1 2020
INVESTOR PRESENTATION q1 2020 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “an
Slide 3: DermTech: leader in precision dermatology
DermTech, Inc. (NASDAQ: DMTK) is a leader in precision dermatology enabled by a non-invasive skin genomics platform. DERMTECH Mission: To bring precision to the practice of dermatology through non-invasive genomic assessment of the skin. We address very large market opportunities in skin cancer and
Slide 4: Defining a New Category & Paradigm Shift
DermTech: Defining a New Category & Paradigm Shift A Better Diagnostic Solution for Dermatology Subjective Visual Assessment Surgical Biopsy Subjective Histopathology Adhesive Patch Sample Collection Genomic Analysis CLIA/CAP Commercial Lab Physician Report (within 72 hrs.) SUBJECTIVE LOW ACCURACY I
Slide 5: Genomic Innovations Are Less Invasive, More Accurate, Less Expensive
Genomic Innovations Are Less Invasive, More accurate, and less expensive CANCER COMPANY OLD STANDARD OF CARE NEW-GEN DIAGNOSTIC Breast Colorectal Thyroid Heart Lung Skin
Slide 6: Leadership Team
Leadership Team John Dobak, MD Chief Executive Officer Todd Wood Chief Commercial Officer Kevin Sun, MS, MBA Chief Financial Officer Zuxu Yao, PhD Chief Scientific Officer Burkhard Jansen, MD Chief Medical Officer Claudia Ibarra Chief Operating Officer Founder & Chairman, 10xBio (aesthetic medicine
Slide 7: Board of Directors
Board of Directors Matt Posard Chairman Former Head of Global Sales and General Management Illumina, Biosite, Genprobe Cynthia Collins Board Member CEO Editas Medicine, Clariant, Human Longevity, GE Healthcare Enrico Picozza Board Member Partner HLM, Applied Biosystems, RubiconMD, Spinal Kinetics He
Slide 8: Skin Cancer: Melanoma, Basal Cell, and Squamous Cell Carcinoma
Skin Cancer Melanoma, Basal Cell, and Squamous Cell Carcinoma More people are diagnosed with skin cancer than all other cancers combined and 1 in 5 Americans will develop skin cancer by the age of 70 A Snapshot of the Skin Cancer Market Annual cost of treatment is estimated to be $8.1 billion, $4.8
Slide 9: Significant Market Opportunity Within Dermatologic Cancer
Significant Market Opportunity Within Dermatologic Cancer US melanoma diagnoses increased 53% from 2008 to 2018 US non-melanoma skin cancer diagnoses increased 77% from 1994 to 2014 ~4.0 Million Melanoma Biopsies ~11 Million Nonmelanoma Biopsies 15+ Million Total Biopsies ~15+ Million Total Biopsies
Slide 10: Significant Opportunity in Medicare for Melanoma Early Detection
Guy GP, et al. MMWR, 2015; 64:591 Anderson A, et al., JAMA Dermatology, 2018, 154(5):569 2020 Clinical Laboratory Fee Schedule: https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/20clabq1 Gould LJ et al., RIMED, 2016; February Webpage, 3
Slide 11: Early Detection of Melanoma Is Critical to Patient Survival
Early Detection of Melanoma Is Critical to Patient Survival When Diagnosed at the Local Stage 98% When Diagnosed at the Regional Stage 64% When Diagnosed at the Distant Stage 23% 1. Cancer Facts & Figures 2018. American Cancer Society. 2. Hanke CW, Carcinoma and Keratoses, 1:2 2019 Not Skin Cancer S
Slide 12: Subjective Pathology Assessment: Diagnostic Inaccuracy and Unnecessary Surgery
Subjective Pathology Assessment Unmet Need: Melanoma’s Challenging Diagnostic Pathway (cont’d) Diagnostic Inaccuracy and Unnecessary Surgery Anderson A, et al., JAMA Dermatology, 2018; doi:10.1001/jamadermatol.2018.0212 Elmore JG, et al. BMJ. 2017;357:j2813. Strazzula L, et al. Journal of the Americ
Slide 13: DermTech's Pigmented Lesion Assay (PLA)
Genomic Material Purified from Patch Enhanced Early Melanoma Detection: Non-invasive Gene Expression Test 1 Dermtech’s pigmented lesion assay (pla) Non-invasive adhesive patch collection Avoids unnecessary surgery Improved patient care Highly accurate Low probability of missed melanoma (<1%) 100% of
Slide 14: DermTech's PLA Performance Metrics
DermTech’s PLA Performance Metrics Performance Metric Biopsy & Histology PLA Test Improvement Probability Of Missed Melanoma1 17% 1% 17x Biopsies Per Melanoma2 25 2.7 10x Wide Excisions Per Melanoma2,3 5.2 1.6 3x Cost Per Lesion Tested4 ~$1,000 $760 -$240 Fewer biopsies while missing fewer melanomas
Slide 15: Benefits Across the Value Chain
Benefits Across the Value Chain PAYERS Fewer surgical costs and surveillance costs Earlier detection and avoidance of missed melanoma avoids costlier later-stage diagnosis Cost reduction over current standard of care for biopsy and histopathology PHYSICIANS Enhances early detection, lowers probabili
Slide 16: PLA Test: Significant Clinical Validation
PLA Test: Significant Clinical Validation MILESTONE STATUS SAMPLE SIZE Analytical Validation ✔ Complete 125 Clinical Validation – pathology ✔ Complete 555 Clinical Validation – mutation ✔ Complete 626 Clinical Utility ✔ Complete 45 Derms Real-World Utility ✔ Complete 381 1-Year Follow-up ✔ Complete
Slide 17: Patent Protection
RNA=ribonucleic acid. Patent Protection Broad methods covering RNA analysis of adhesive patch collected skin: 7,183,057 Method of detection of biological factors in epidermis: 6,720,145 Broad claims for melanoma gene classifier: 9,057,109 Broad claims for melanoma gene classifier: 10,407,729 Issued
Slide 18: Cancer Detection Breakthrough Case Study
Cancer Detection Breakthrough Case Study Background DermTech Results 28-year-old female Family history of melanoma Complained of bug bite Refused surgical biopsy PLA test was positive Histopathology revealed 0.5-mm melanoma Curative wide excision performed Case study published in JAMA Dermatology1 1
Slide 19: Commercial Activities
COMMERCIAL ACTIVITIES
Slide 20: Commercial Lab Operations
Commercial Lab Operations CLIA-licensed laboratory in all 50 states CAP certified ~9000-square-foot commercial lab space Current capacity 50,000 tests per year Adding automation to increase to 100k+/year Expansion preparation to 500k/year PLA assay turnaround time is ~72 hours
Slide 21: Commercial Growth Strategy
Commercial Growth Strategy 1 Establish broad payer coverage Leverage new Medicare coverage to Medicare Advantage plans and commercial payers 2 Create consistent core clinician message and position to accelerate impact Improved and tested professional campaign Actively educate and engage the patient
Slide 22: PLA Test vs Dermatopathology: Core Clinician Positioning
PLA Test Dermatopathology VS Samples the entire lesion Provides additional objective genomic information Measures malignant changes that cannot be seen visually Samples less than 1-2% of a potentially partial surgical biopsy Relies on subjective visual criteria Morphologic changes must be present an
Slide 23: Actively Educate and Mobilize the Patient Voice
Mobilize the Patient Actively Educate and Mobilize the Patient Voice Engage patients to amplify our story
Slide 24: Establishing 2019 to 2021 Expansion Roadmap
CMS: Centers for Medicare & Medicaid Services CPT: Current Procedural Terminology Establishing 2019 to 2021 Expansion Roadmap 2019 Expansion 2020-to-2021 Expansion Roadmap Creating territory valuation model based on key procedure and practice inputs Medicare and Commercial CPT codes (weight CMS) Dia
Slide 25: The Dermatology Call-Point Favors Adoption
Source: Market Profile of US Dermatologists, Cegedim 2015. The Dermatology Call-Point Favors Adoption HIGHLY FRAGMENTED HIGHLY DEPENDENT ON GOVERNMENT PAYERS EXCEEDINGLY BUSY OPEN TO MEETING SALES REPRESENTATIVES
Slide 26: Pipeline
PIPELINE
Slide 27: DermTech Product Pipeline
LINC: Long Intergenic Non-protein Coding RNA 518; PCR: Polymerase Chain Reaction; Mut: Mutation; PRAME: Preferentially Expressed Antigen in Melanoma; R/O: Rule Out; Tx: Treatment; TERT: Telomerase Reverse Transcriptase DermTech Product Pipeline Product Test Purpose Assay Type Gene Targets Stage Pigm
Slide 28: Research Partners: Strong Collaborations With Big Pharma
Research Partners Strong Collaborations With Big Pharma ~$9.5 million in research programs booked to date Robust pipeline of opportunities and pending contracts Independent performance development Expansion to late-stage trials (phase ll, lll) Indication* Pilot Phase 1 Phase 2 Phase 3 Pemphigus Vulg
Slide 29: Financial Highlights
Financial Highlights
Slide 30: Medicare Coverage: A Significant Milestone for Test Unit and Revenue Growth
Source: DermTech, Inc., Capital IQ, Bloomberg. Medicare Coverage A Significant Milestone for Test Unit and Revenue Growth DermTech Quarterly Billable Sample Volume, 2019 Company Test CMS Approval Pre-Approval Revenue (MM) Year 1 Revenue (MM) Year 1 Gross Margin Year 1 Opex % Rev Exact Sciences Colog
Slide 31: Financial Strategy
Financial Strategy Longer-Term Initiatives (2022 and beyond) Near-Term Initiatives (2020 and 2021) Increase proportion of Medicare in payer mix Leverage Medicare pricing for commercial payer negotiations Optimize gross margin opportunities via automation and expansion location Prioritize and acceler
Slide 32: DermTech Summary
DermTech Summary Unique non-invasive skin genomics platform with virgin call point in dermatology Creates new category and paradigm shift in dermatology Multiple large market opportunities leveraging the same sample collection platform and sales and clinical laboratory infrastructure Commercial stag